Breakthrough pain in patients referred to pain clinics: The Italian pain network retrospective study

Advances in Therapy

Volumn 29, Issue 5, 2012, Pages 464-472

  Gatti, Antonio ^a   Mediati, Rocco D ^b   Reale, Carlo ^c   Cuomo, Arturo ^d   Vellucci, Renato ^b   Russo, Gennaro ^d   Costantini, Amedeo ^e   Canneti, Alessandra ^c   Luzi, Marta ^c   Mammucari, Massimo ^f   Sabato, Alessandro Fabrizio ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f Primary Care   (Italy)

Author keywords

Breakthrough pain; Cancer pain; Non cancer pain; Opioid therapy; Pain assessment; Pain exacerbation; Pain intensity; Pain predictability

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE;

ABDOMINAL CANCER; ADULT; ARTICLE; BREAKTHROUGH PAIN; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HEALTH CENTER; HEALTH SURVEY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; PAIN ASSESSMENT; PATIENT REFERRAL; RETROSPECTIVE STUDY; THORAX CANCER;

ANALGESICS, OPIOID; BREAKTHROUGH PAIN; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ITALY; MALE; NEOPLASMS; PAIN; PAIN CLINICS; PAIN MEASUREMENT; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84863725655     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0022-z     Document Type: Article

References (30)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncology (Williston Park). 1989;3(Suppl.):25-9. (Pubitemid 19224897)
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-81. (Pubitemid 20187930)
3. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-34. (Pubitemid 29199908)
4. Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149:476-82.
5. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195-206. (Pubitemid 40311842)
6. Mercadante S, Radbruch L, Caraceni A, et al.; Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94:832-9. (Pubitemid 34132314)
7. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3:1-6.
8. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-83. (Pubitemid 38771657)
9. Mercadante S, Costanzo BV, Fusco F, et al. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manage. 2009;38:554-60.
10. Mercadante S, Zagonel V, Breda E, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manage. 2010;40:183-90.
11. Greco MT, Corli O, Montanari M, et al.; Writing Protocol Committee; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011;27:9-18.
12. Mercadante S, Villari P, Casuccio A. An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Support Care Cancer. 2011;19:979-83.
13. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med. 2001;15:243-6. (Pubitemid 32479462)
14. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and non cancer pain, part 1: prevalence and characteristics. J Opioid Manag. 2010;6:97-108.
15. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14-27.
16. Andersson DA, Gentry C, Alenmyr L, et al. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol. Nat Commun. 2011;22:551.
17. Caraceni A, Hanks G, Kaasa S, et al.; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-68.
18. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181-90.
19. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther. 2010;48:138-45.
20. Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008;30:469-81. (Pubitemid 351483922)
21. Lennernäs B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005;59:249-53. (Pubitemid 40208864)
22. Darwish M, Kirby M, Robertson P Jr, Hellriegel E, Jiang JG. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet. 2006;45:843-50. (Pubitemid 44182277)
23. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv. 2009;6:543-52.
24. Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage. 2011;41:358-66.
25. Portenoy RK, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617-24.
26. Radbruch L, Torres LM, Ellershaw JE, et al. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer. 2012;20:565-73.
27. Taylor D, Galan V, Weinstein SM, et al.; Fentanyl Pectin Nasal Spray 043 Study Group. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol. 2010;8:184-90.
28. Mercadante S. Managing breakthrough pain. Curr Pain Headache Rep. 2011;15:244-9.
29. Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012. Epub ahead of print.
30. Sabato AF. Idiopathic breakthrough pain. A new hypothesis. Clin Drug Investig. 2010;30:27-9.